Moreover, the correlation between this metabolite and TRIP6 and ERBB2, two genes that were recently identified to play a role in the pathophysiology of NAFLD (Machado et al., 2015; Wang et al., 2016), suggests that upregulation of these genes can be induced via circulating metabolites. The gene discussed is TRIP6; the disease is metabolic dysfunction-associated steatotic liver disease.